MONTREAL, Oct. 21, 2024 /CNW/ - AbbVie (ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or ...
In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...
Zacks Investment Research on MSN
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...
B-cell lymphomas constitute a heterogeneous group of malignancies derived from B-lymphocytes, with diffuse large B-cell lymphoma (DLBCL) representing the most common subtype. Among these, double-hit ...
Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio ...
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with ...
Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback